{"id":456221,"date":"2021-03-11T13:19:07","date_gmt":"2021-03-11T18:19:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=456221"},"modified":"2021-03-11T13:19:07","modified_gmt":"2021-03-11T18:19:07","slug":"harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/","title":{"rendered":"Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., March  11, 2021  (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting Week 1 will be held virtually from April 10-15, 2021. Posters will be available on Harpoon\u2019s website following the presentations.<\/p>\n<p>Full abstracts of the following presentations are available online at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kbau_c5_Jfy5cEEBtf2p8LYSBeStQDieIg-8E3T-_oK3f2u_tRm2Yn_iCfHbI-YvMN9f2duf7fC2FxO-97Tp7w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.aacr.org<\/a>:<\/p>\n<p>\n        <strong>Title: <\/strong>FLT3-targeting TriTACs are T cell engagers for treatment of acute myeloid leukemia\u00a0\u00a0\u00a0\u00a0 <br \/><strong>Abstract #: <\/strong>913<br \/><strong>Presenter:<\/strong> Richard J. Austin, Ph.D.<br \/><strong>Session Category: <\/strong>Experimental and Molecular Therapeutics<br \/><strong>Session Title:<\/strong> PO.ET01.01 &#8211; Antibody Technologies <br \/><strong>Date\/time:<\/strong> April 10, 2021, 8:30 a.m &#8211; 11:59 p.m. EDT<\/p>\n<p>\n        <strong>Title: <\/strong>ProTriTAC is a modular and robust T cell engager prodrug platform with therapeutic index expansion observed across multiple tumor targets <br \/><strong>Abstract #: <\/strong>933<br \/><strong>Presenter:<\/strong> S. Jack Lin, Ph.D.<br \/><strong>Session Category: <\/strong>Experimental and Molecular Therapeutics<br \/><strong>Session Title:<\/strong> PO.ET01.02 &#8211; Biochemical Modulators of the Therapeutic Index <br \/><strong>Date\/time:<\/strong> April 10, 2021, 8:30 a.m &#8211; 11:59 p.m. EDT<\/p>\n<p>\n        <strong>Title: <\/strong>Combinatorial antitumor effects of CD3-based trispecific T cell activating constructs (TriTACs) and checkpoint inhibitors in preclinical models <br \/><strong>Abstract #: <\/strong>1573<br \/><strong>Presenter:<\/strong> Mary Ellen Molloy, Ph.D.<br \/><strong>Session Category: <\/strong>Immunology<br \/><strong>Session Title:<\/strong> PO.IM02.02 &#8211; Combination Immunotherapies<br \/><strong>Date\/time:<\/strong> April 10, 2021, 8:30 a.m &#8211; 11:59 p.m. EDT<\/p>\n<p>\n        <strong>About Harpoon Therapeutics<\/strong>\n      <\/p>\n<p>Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body\u2019s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient\u2019s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC<sup>\u00ae<\/sup>) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1\/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1\/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1\/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1\/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC\u2122\u00a0platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CBSQ_IDL-7RP7kPxM7zNLQ8kYbk_vyri1mT5OyrSRcQDFfrUVwOhJWpPMlzmok1n-JjtQXL04bq7uj9cOmlb7h2p2TxIq3jpX4h_FYJx210ANxrXCMIzVFrcgZU2VxEJ_eznauEEAMokDoX3GRoQqBnuudLKF2P5LTsF1MKvwjiYIq8PKLW5Ld5jlMgu2g02xFv6SL_QhUnmsOQ3mtwmeM2YxJcPOJV-TnUMh8AFnW8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.harpoontx.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>Harpoon Therapeutics, Inc.<br \/>Georgia Erbez<br \/>Chief Financial Officer<br \/>650-443-7400<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PYphTuQJFExeKWjqy_65JhYCD9HaSGtxJDe97IYJHc3IwbZLS7wwE-tPVYsKVqABOZiLhND3Ej2moLhIIccKD1aAcVJ4bws_cJuFt2nZJbE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">media@harpoontx.com<\/a><\/p>\n<p>Westwicke ICR<br \/>Robert H. Uhl<br \/>Managing Director<br \/>858-356-5932 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Qkrc3K3IQtrcAHsz1-qIS0ljkHsZR4k5js5CrEiLWtgh_bI9x3Sqhk_3knSDvRcoPcO9ZwAi0oixnvv1wivrRyn_f4nNrT6VrkQjuMBnIhc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">robert.uhl@westwicke.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODY5OCM0MDYwMzAzIzIxMjU4MTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ecc5a696-a923-4c2d-9d8e-666c9b6c33a5\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting Week 1 will be held virtually from April 10-15, 2021. Posters will be available on Harpoon\u2019s website following the presentations. Full abstracts of the following presentations are available online at www.aacr.org: Title: FLT3-targeting TriTACs are T cell engagers for treatment of acute myeloid leukemia\u00a0\u00a0\u00a0\u00a0 Abstract #: 913Presenter: Richard J. Austin, Ph.D.Session Category: Experimental and Molecular TherapeuticsSession Title: PO.ET01.01 &#8211; Antibody Technologies Date\/time: April 10, 2021, 8:30 a.m &#8211; 11:59 p.m. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-456221","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting Week 1 will be held virtually from April 10-15, 2021. Posters will be available on Harpoon\u2019s website following the presentations. Full abstracts of the following presentations are available online at www.aacr.org: Title: FLT3-targeting TriTACs are T cell engagers for treatment of acute myeloid leukemia\u00a0\u00a0\u00a0\u00a0 Abstract #: 913Presenter: Richard J. Austin, Ph.D.Session Category: Experimental and Molecular TherapeuticsSession Title: PO.ET01.01 &#8211; Antibody Technologies Date\/time: April 10, 2021, 8:30 a.m &#8211; 11:59 p.m. &hellip; Continue reading &quot;Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-11T18:19:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODY5OCM0MDYwMzAzIzIxMjU4MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021\",\"datePublished\":\"2021-03-11T18:19:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\\\/\"},\"wordCount\":466,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODY5OCM0MDYwMzAzIzIxMjU4MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\\\/\",\"name\":\"Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODY5OCM0MDYwMzAzIzIxMjU4MTI=\",\"datePublished\":\"2021-03-11T18:19:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODY5OCM0MDYwMzAzIzIxMjU4MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODY5OCM0MDYwMzAzIzIxMjU4MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/","og_locale":"en_US","og_type":"article","og_title":"Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021 - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting Week 1 will be held virtually from April 10-15, 2021. Posters will be available on Harpoon\u2019s website following the presentations. Full abstracts of the following presentations are available online at www.aacr.org: Title: FLT3-targeting TriTACs are T cell engagers for treatment of acute myeloid leukemia\u00a0\u00a0\u00a0\u00a0 Abstract #: 913Presenter: Richard J. Austin, Ph.D.Session Category: Experimental and Molecular TherapeuticsSession Title: PO.ET01.01 &#8211; Antibody Technologies Date\/time: April 10, 2021, 8:30 a.m &#8211; 11:59 p.m. &hellip; Continue reading \"Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-11T18:19:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODY5OCM0MDYwMzAzIzIxMjU4MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021","datePublished":"2021-03-11T18:19:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/"},"wordCount":466,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODY5OCM0MDYwMzAzIzIxMjU4MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/","name":"Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODY5OCM0MDYwMzAzIzIxMjU4MTI=","datePublished":"2021-03-11T18:19:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODY5OCM0MDYwMzAzIzIxMjU4MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODY5OCM0MDYwMzAzIzIxMjU4MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-announces-poster-presentations-and-publication-of-abstracts-for-aacr-annual-meeting-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=456221"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456221\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=456221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=456221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=456221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}